PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Transplantation. Author manuscript; available in PMC 2010 November 18.
Published in final edited form as:
PMCID: PMC2987655
NIHMSID: NIHMS246754

TACROLIMUS IN PEDIATRIC RENAL TRANSPLANTATION1

Abstract

Tacrolimus was used as the primary immunosuppressive agent in 69 pediatric renal transplantations between December 17, 1989, and June 30, 1995. Children undergoing concomitant or prior liver and/or intestinal transplantation were excluded from analysis. The mean recipient age was 10.3±5.0 years (range, 0.7–17.5 years). Seventeen (24.6%) children were undergoing retransplantation, and six (8.7%) had a panel reactive antibody level of 40% or higher. Thirty-nine (57%) cases were with cadaveric kidneys, and 30 (43%) were with living donors. The mean donor age was 28.0±14.7 years (range, 1.0–50.0 years), and the mean cold ischemia time for the cadaveric kidneys was 27.0±9.4 hr. The antigen match was 2.7±1.2, and the mismatch was 3.1±1.2. All patients received tacrolimus and steroids, without antibody induction, and 26% received azathioprine as well. The mean follow-up was 32±20 months. One- and 4-year actuarial patient survival rates were 100% and 95%. One- and 4-year actuarial graft survival rates were 99% and 85%. The mean serum creatinine level was 1.2±0.8 mg/dl, and the calculated creatinine clearance was 82±26 ml/min/1.73 m2. The mean tacrolimus dose was 0.22±0.14 mg/kg/day, and the level was 9.5±4.8 ng/ml. The mean prednisone dose was 2.1±4.9 mg/day (0.07±0.17 mg/kg/day), and 73% of successfully transplanted children were off prednisone. Seventy-nine percent were not taking any antihypertensive medications. The mean serum cholesterol level was 158±54 mg/dl. The incidence of delayed graft function was 4.3%. The incidence of rejection was 49%, and the incidence of steroid-resistant rejection was 6%. The incidence of rejection decreased to 27% in the most recent 26 cases (January 1994 through June 1995). The incidence of new-onset diabetes was 10.1%; six of the seven affected children were able to be weaned off insulin. The incidence of cytomegalovirus disease was 13%, and that of posttransplant lymphoproliferative disorder was 10%; the incidence of posttransplant lymphoproliferative disorder in the last 40 transplants was 5% (two cases). All of the children who developed posttransplant lymphoproliferative disorder are alive and have functioning allografts. Based on this data, we believe that tacrolimus is a superior immunosuppressive agent in pediatric renal transplant patients, with excellent short- and medium-term patient and graft survival, an ability to withdraw steroids in the majority of patients, and, with more experience, a decreasing rate of rejection and viral complications.

Tacrolimus is a relatively new immunosuppressive agent, approved by the FDA in June 1994, for use in liver transplant recipients (16). It has, however, also been used in adults undergoing renal transplantation, both as a primary and as a rescue agent, in many centers around the world (714). For the same toxicities, principally nephrotoxicity, neurotoxicity, and diabetogenicity (1520), it has been shown to have more immunosuppressive efficacy than cyclosporine-based therapy (8, 9, 21). This has been manifested by improved short- and projected long-term graft survival, and an increased ability to wean steroids completely (8,9,21,22).

There has been rather less experience with tacrolimus in pediatric renal transplantation, although the early experience has been encouraging (2328). In this report, our cumulative experience with tacrolimus as the primary immunosuppressive agent in pediatric renal transplant recipients is summarized, and the lessons we have learned and the details of our current strategies for using this agent are described.

PATIENTS AND METHODS

Between December 17, 1989, and June 30, 1995, tacrolimus was used as a primary immunosuppressive agent in 69 renal transplantations performed in 68 pediatric patients at the Children’s Hospital of Pittsburgh (CHP; Table 1). Children who had undergone or were undergoing concomitant liver and/or intestinal transplantation were not included in this analysis. The mean recipient age was 10.3±5.0 years (range, 0.7–17.5 years). Five (7.2%) children were under 2 years of age at the time of transplantation, and another eight (11.6%) were between 2 and 5 years of age. Seventeen (24.6%) children were undergoing retransplantation; eleven (15.9%) received their second, five (7.2%) received their third, and one (1.4%) received his fourth transplant. Nine patients had been transplanted previously elsewhere, and eight had received transplants previously at CHP. Six (8.7%) children had a panel reactive antibody (PRA) level over 40%. The causes of end-stage renal disease are listed in Table 2.

Table 1
Recipient and donor demographics: time period 12/17/89–6/30/95
Table 2
Causes of end-stage renal disease

Thirty-nine (57%) transplants were with cadaveric kidneys, and 30 (43%) were with living donors (28 parents, 1 grandmother, and 1 adoptive father; Table 1). The mean donor age was 28.0±14.7 years (range, 1.0–50.0 years). The mean cold ischemia time for the cadaveric kidneys was 27.0±9.4 hr. Eight (20.5%) of the cadaveric cases were with donors less than 5 years of age, and of these, two were with pediatric en bloc kidneys from donors 1 year and 1.2 years of age. All of the recipients of these pediatric kidneys were over 10 years of age. The mean number of antigen matches and mismatches was 2.7±1.2 and 3.1±1.2, respectively.

Immunosuppression was with tacrolimus (26, 27, 29); 26% of patients received azathioprine as well. Induction antilymphocyte therapy was not used. Tacrolimus was given orally at a dose of 0.15 mg/kg before surgery. After surgery, it was begun as a continuous intravenous infusion of 0.075–0.10 mg/kg/day. Once patients were able to tolerate a diet, they were started on oral tacrolimus, 0.15 mg/kg twice a day, and the intravenous tacrolimus was gradually tapered off. Plasma levels were followed initially; for the past 2 years, whole blood EMx levels have been used. Current tacrolimus target levels and steroid dosing guidelines are shown in Table 3.

Table 3
Tacrolimus target levels

Statistical analysis

The patient survival rate was calculated from the date of kidney transplantation until death, and the graft survival rate was calculated from the date of kidney transplantation until graft failure, retransplantation, or patient death. Survival curves were generated using the Kaplan-Meier (product limit) method and were compared using the log-rank (Mantel-Cox) test. All tests were two-tailed. A P-value less than 0.05 was considered statistically significant.

Until June 1994, when tacrolimus was approved by the U.S. Food and Drug Administration, all transplants were done under a protocol approved by the Human Rights Committee of CHP.

RESULTS

The mean follow-pup was 32±20 months.

The overall 1- and 4-year actuarial patient survival rates were 100% and 95% (Fig. 1, Table 3). Two patients died 3.3 years and 1.3 years after transplantation. The first patient was a 17.4-year-old white female with end-stage renal disease secondary to ureteral reflux who lost her allograft to noncompliance 1.8 years after transplantation and died on dialysis (off immunosuppression) 1.5 years later of uncertain causes. The second was a 17.5-year-old black male with sickle cell anemia, who had a difficult course after transplantation, including fungal infection (Rhizopus) of his left native kidney, several episodes of rejection, and recurrent sickle crises. He rather suddenly developed fungal sepsis 1.3 years after transplantation, with a mycotic aneurysm of the superior mesenteric artery and associated infarction of his entire gastrointestinal tract.

Figure 1
Kaplan-Meier patient and graft survival rates for pediatric kidney transplantation from December 14, 1989, to June 30, 1995. The number in parentheses represents the number of patients at risk.

The overall 1- and 4-year actuarial graft survival rates were 99% and 85% (Fig. 1, Table 4). Eight patients lost their allografts, three to chronic rejection 1.1, 2.8, and 4.2 years after transplantation, three to recurrent disease (hemolytic-uremic syndrome at 0.02 years, membranoproiiferative glomerulonephritis type II at 3.4 years, and focal segmental glomerulosclerosis at 2.1 years), one to death at 1.3 years, and one to noncompliance at 1.8 years (Table 4). One- and 4-year actuarial graft survival rates in selected subgroups are shown in Table 5. Interestingly, cadaveric organ recipients did as well as living donor organ recipients (the numerical superiority in the cadaver group at 4 years, 89% vs. 81%, was not statistically different; four patients in each group lost their kidney). Retransplant recipients were also not statistically worse than first-transplant recipients, but there was an increasing difference in graft survival at 4 years (75% vs. 90%). Patients with high PRA levels did significantly worse than patients with low PRA levels at 4 years (42% vs. 93%; P=0.0003), and the 1-year outcomes were also worse (83% vs. 100%). Recipient age had no effect on graft survival, nor did donor age. Of note, all five recipients under 2 years of age and seven of the eight recipients under 5 years of age had functioning allografts. In addition, the 1- and 4-year graft survival rates for the recipients of kidneys from donors 5 years of age or younger were both 100%; one recipient did go on to lose his kidney to chronic rejection at 4.2 years. Rejection was also not associated with statistically worse graft survival, but there was a trend toward worse outcomes at 4 years (78% vs. 97%) in patients who experienced rejection.

Table 4
Actuarial patient and graft survival ratesa
Table 5
Subgroup actuarial (Kaplan-Meier) graft survival rates

The mean serum creatinine level was 1.2±0.8 mg/dl, and the calculated creatinine clearance was 82±26 ml/min/1.73 m2 (30). The mean blood urea nitrogen level was 25±13 mg/dl (Table 6). These values were relatively stable over time (Table 7).

Table 6
Creatine, tacrolimus, and steroid levels
Table 7
Creatine, tacrolimus, and steroid values over time

The mean tacrolimus dose was 7.8±6.8 mg/day (0.22±0.14 mg/kg/day), and the mean level was 9.5±4.8 ng/ml (Tables 6 and and7).7). The mean prednisone dose was 2.1±4.9 mg/day (0.07±0.17 mg/kg/day); for children still on prednisone, it was 7.1±6.8 mg/day (0.3±0.3 mg/kg/day). Seventy-three percent of children transplanted successfully were taken off prednisone (Table 6). Steroids were withdrawn at a mean time of 7.9±5.2 months after transplantation. Ten percent of patients had to have steroids restarted. Serum creatinine was comparable among patients taken off steroids (1.0±0.4 mg/dl), patients restarted on steroids (1.1±0.7 mg/dl), and patients who were never taken off steroids (1.4±0.4 mg/dl).

Delayed graft function was seen in three (4.3%) patients (Table 8); two required dialysis. All of the delayed graft function was seen in cadaveric cases.

Table 8
Complications

Rejection was seen in 34 (49%) patients, and was biopsy proven in over 90% of the cases (Table 8). Over 90% of rejection episodes were seen within the first 2 weeks after transplantation. Steroid-resistant rejection was seen in four (6%) patients; 88% of the rejection episodes were treated with steroids and modification of the tacrolimus dosage. There was a decrease over time in the incidence of rejection; between December 1989 and December 1993, rejection was noted in 63% (27/43) of the patients; between January 1994 and June 1995, the incidence was 27% (7/26; P=0.004). This was probably related to maintaining higher tacrolimus levels during the first 2 weeks after transplantation in the more recently transplanted patients (see Discussion).

New-onset diabetes was observed in seven (10.1%) patients (Table 8). This was a temporary complication in six children, and normoglycemia off insulin was achieved within several months after gradually reducing both the tacrolimus and steroid dosages. The one patient who remained insulin dependent was the sickle cell patient described above, who had several rejection episodes and required high doses of both tacrolimus and steroids.

Cytomegalovirus (CMV), either asymptomatic infection or symptomatic disease, was observed in nine (13.0%) children (Table 6); in all of these cases, the recipients were seronegative and received kidneys from seropositive donors. All patients received routine prophylaxis with high-dose oral acyclovir; in addition, intravenous ganciclovir and CMV hyperimmune globulin was given to the seropositive donor/seronegative recipient cases. All affected children responded promptly to intravenous ganciclovir and reduction of immunosuppression. In a few cases, it was possible to diagnose CMV infection by antigenemia testing (31), before symptomatic disease developed, and treat preemptively with ganciclovir.

Early (4–6 months after transplantation) Epstein-Barr virus-related posttransplant lymphoproliferative disorder (PTLD) was seen in seven (10.1%) patients (Table 8). PTLD was seen in the liver, gastrointestinal tract, and/or allograft. These cases behaved much like viral infections; all disappeared with cessation of immunosuppression and intravenous ganciclovir. Immunosuppression was eventually reintroduced, and none of the children died or lost their allograft. Of note, the incidence of PTLD seemed to decrease as more experience was acquired with tacrolimus. From December 1989 to December 1992, five (17%) cases of PTLD were seen, whereas from January 1993 until June 1995, two (5%) cases were reported. This was probably related both to more aggressive tapering of immunosuppression beginning 6–8 weeks after transplantation and, more recently, monitoring of the Epstein-Barr virus antigenemia to allow for reduction of immunosuppression and preemptive treatment with ganciclovir before PTLD could develop.

In addition, there was one late case of Burkitt’s lymphoma in a 11.8-year-old boy, which developed 3.8 years after transplantation and 3 months after his maintenance immunosuppression was increased by 50%. This patient received chemotherapy with cyclophosphamide, vincristine, methotrexate, adriamycin, etoposide, cytosine arabinoside, and prednisone, which was successful in eradicating the lymphoma. His allograft function remains good (serum creatinine, 1.3 mg/dl), and he was recently restarted on tacrolimus, at 1 mg p.o. q.d.

Finally, there was a late case of non-Burkitt’s lymphoma in a 16.4-year-old boy who received a transplant in Pittsburgh but was followed elsewhere, which was diagnosed 4.3 years after transplantation. The patient was begun on a chemotherapy regimen identical to that described above and, in addition, he received local radiation therapy to the brain stem. Immunosuppression was discontinued, and renal function has remained normal (serum creatinine, 1.1 mg/dl).

At most recent follow-up, 79% of children with successful transplants were not taking antihypertensive medications. The mean serum cholesterol level was 158±54 mg/dl (Table 9).

Table 9
Follow-up data

Serial heights were reported in all children and were converted to Z-scores. The mean Z-scores were plotted over time for all children and were stratified based on age (under 12 years vs. 12 and over) and steroid dosage (off steroids vs. on) (Figs. 2 and and33 and Table 10). There was enormous variability in growth after transplantation. Clearly, however, children off steroids tended to have more accelerated growth than children on steroids, and children 12 years of age or younger at the time of transplantation tended to achieve better growth than children who received transplants after the age of 12. The most recent Z-score for children 12 and under off steroids was −0.94±1.37; for the five children under 2 years of age (all of whom were off steroids), it was −0.15±0.77.

Figure 2
Plot of Z-scores over time for patients on and off steroids.
Figure 3
Plot of Z-scores over time for patients 12 years and younger vs. patients older than 12 years at the time of transplantation.
Table 10
Z-score (most recent)

DISCUSSION

Tacrolimus has emerged as an efficacious immunosuppressive agent in a wide variety of transplant settings (46, 3237). In our pediatric renal transplant recipients, it has been associated with excellent patient and graft survival and an ability to wean steroids and antihypertensive agents in 73% and 79%, respectively, of children with successful transplants. Growth, particularly in preadolescent children who have been weaned off steroids, has improved substantially and has become normal in many cases. The two major complications that had been seen early in our experience with this agent, a moderately high incidence of rejection on the one hand and an alarming incidence of PTLD on the other, seem to have decreased over time. In the 18-month period from January 1994 to June 1995, the incidence of rejection was 27% (7 of 26 cases), in contrast to the 63% (27 of 43 cases) incidence seen from December 1989 to December 1993. Similarly, in the last 40 cases, PTLD was seen in two (5%) patients, in contrast to the five (17%) cases seen in the first 29 patients. Although this is reassuring, the occurrence of two late lymphomas is of concern, and points to the need for continued surveillance and the importance of maintaining low levels of chronic immunosuppression.

Our current practice calls for patients to receive an oral dose of tacrolimus, 0.15 mg/kg, on call to the operating room. On arrival to the intensive care unit after surgery (all of our children go to the intensive care unit after renal transplantation), intravenous tacrolimus is started at a dose of 0.075–0.10 mg/kg/day, as a continuous infusion. When patients are able to tolerate a diet, they are gradually converted to oral tacrolimus, starting at 0.15 mg/kg p.o. twice a day. Intravenous tacrolimus is not stopped abruptly, but is tapered over several days. The goal is to maintain whole blood IMx levels of 20–25 ng/ml for the first 2 weeks after surgery. It is our impression that maintaining these high target trough levels has been important in reducing the incidence of early rejection. Tacrolimus dosages are then gradually weaned to maintain levels of 15–20 ng/ml by 1 month, 10–15 ng/ml by 3 months, and less than 5 to 8–9 ng/ml chronically (Table 3).

Steroids are begun in the operating room with a bolus of intravenous methylprednisolone, 15–25 mg/kg. A short steroid recycle is then given during their first postoperative week, tapering from 3–10 mg/kg/day to 0.3–1 mg/kg/day. The wide variability reflects a somewhat higher mg/kg dosage in very small children. In the uncomplicated case, steroid tapering is begun 2–3 weeks after surgery, with the goal of discontinuing steroids altogether by 4–8 months after transplantation. Obviously, the tapering schedule is subject to modification in children experiencing rejection. Whenever possible, however, a consciously aggressive approach to reducing immunosuppression, beginning 6–8 weeks after surgery, has, in our view, been instrumental in decreasing the incidence of PTLD. Finally, once steroids have been discontinued and a chronic maintenance dose and level of tacrolimus have been achieved, in the presence of stable renal function, the tacrolimus dose generally should not be adjusted upward (it may, however, need to be decreased to the lowest possible dosage consistent with avoiding rejection). Children do not “outgrow” their tacrolimus dosage, and the consequences of an unindicated increase in the dose can be disastrous. In practice, several pediatric patients have been maintained off steroids with tacrolimus levels of less than 5 ng/ml (which generally means a level of 3.0–4.9 ng/ml), with stable, normal renal function.

Given the excellent patient and graft survival rates obtained under tacrolimus-based immunosuppression, the ability to wean steroids and antihypertensive agents in a high percentage of cases, and the decreasing incidence of both rejection and PTLD as more experience with the agent has been acquired, we believe that tacrolimus is the immunosuppressive drug of choice in children undergoing renal transplantation.

Acknowledgments

We thank Regina Fenton, RN, BSN, Loraine Kaminski, RN, BSN, Jennifer Ovesney, RN, M.J. Grosso, RN, MSN, Deborah Good, RN, BSN, Holly Woods, RN, Jareen Flohr, RN, BSN, Sue Bauder, RN, Sharon Orlofske, RN, and Mark Paynter, RN, BSN, for their help with patient care; Janet Schmelzer for her help with data entry and organization; Kate Carr for her help with slide preparation; and Susan Shandor for her help with typing the manuscript and with table and slide preparation.

Abbreviations

CHP
Children’s Hospital of Pittsburgh
CMV
cytomegalovirus
PRA
panel reactive antibody
PTLD
posttransplant lymphoproliferative disorder

Footnotes

1Presented at the 15th Annual Meeting of the American Society of Transplant Physicians, May 26–30, 1996, Dallas, Texas.

References

1. Starzl TE, Todo S, Fung J, et al. FK506 for human liver, kidney, and pancreas transplantation. Lancet. 1989;2:1000. [PMC free article] [PubMed]
2. Todo S, Fung JJ, Starzl TE. Liver, kidney, and thoracic organ transplantation under FK506. Ann Surg. 1990;212:295. [PubMed]
3. Fung JJ, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs. cyclosporine. Transplant Proc. 1991;23(6):2977. [PMC free article] [PubMed]
4. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation under FK506 immunosuppression. Ann Surg. 1994;220:297. [PubMed]
5. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 1994;344:423. [PubMed]
6. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110. [PubMed]
7. Starzl TE, Fung JJ, Jordan M, et al. Kidney transplantation under FK506. JAMA. 1990;264:63. [PMC free article] [PubMed]
8. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation. 1995;59:485. [PMC free article] [PubMed]
9. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK5067prednisone vs FK506/azathioprine/prednisone in renal transplant patients. Transplant Proc. 1995;27(1):814. [PMC free article] [PubMed]
10. Jordan M, Shapiro R, Vivas C, et al. FK506 rescue for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation. 1994;57(6):860. [PMC free article] [PubMed]
11. Laskow DA, Vincenti F, Neylan J, Mendez R, Matas A. Phase II FK506 multicenter concentration control study. One-year follow-up. Transplant Proc. 1995;27(1):809. [PubMed]
12. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: results of late phase II study. Transplant Proc. 1993;25 (1 Pt 1):649. [PubMed]
13. Ochiai T, Ishibashi M, Fukao K, et al. Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc. 1995;27(1):50. [PubMed]
14. Schleibner S, Kraus M, Wagner K, et al. FK 506 versus cyclosporin in the prevention of renal allograft rejection—European pilot study: six-week results. Transpl Int. 1995;8:86. [PubMed]
15. Demetris AJ, Banner B, Fung JJ, Shapiro R, Jordan M, Starzl TE. Histopathology of human renal allograft function under FK506: a comparison with cyclosporine. Transplant Proc. 1991;23 (1 Pt 2):944. [PMC free article] [PubMed]
16. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol. 1993;17(1):60. [PubMed]
17. Shapiro R, Fung JJ, Jain A, Parks P, Todo S, Starzl TE. The side effects of FK 506 in humans. Transplant Proc. 1990;22:35. [PMC free article] [PubMed]
18. Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 versus cyclosporine-treated kidney transplant recipients. Transplant Proc. 1991;23(6):3169. [PMC free article] [PubMed]
19. Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis. 1988;12:11. [PubMed]
20. Boudreaux J, McHugh L, Canafax D, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44:376. [PubMed]
21. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation. 1995;60(12):1384. [PubMed]
22. Shapiro R, Jordan ML, Scantlebury VP, et al. Tacrolimus in renal transplantation. Transplant Proc. 1996;28(4):2117. [PMC free article] [PubMed]
23. Starzl TE. Pediatric renal transplantation under FK506 immunosuppression. Transplant Proc. 1991;23:3075. [PMC free article] [PubMed]
24. Schneck F, Jordan M, Jensen C, et al. Pediatric renal transplantation under FK506 immunosuppression. J Urol. 1992;147:1585. [PubMed]
25. Ellis D, Shapiro R, Jordan ML, et al. Comparison of FK506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol. 1994;8:193. [PubMed]
26. Scantlebury V, Shapiro R, Tzakis A, et al. Pediatric kidney transplantation at the University of Pittsburgh. Transplant Proc. 1994;26(1):46. [PMC free article] [PubMed]
27. Shapiro R, Tzakis A, Scantlebury V, et al. Improving results of pediatric kidney transplantation. J Am Coll Surg. 1994;179(4):424. [PMC free article] [PubMed]
28. Shapiro R, Scantlebury V, Jordan ML, et al. FK506 in pediatric kidney transplantation—primary and rescue experience. Pediatr Nephrol. 1995;9:S43. [PMC free article] [PubMed]
29. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506 in renal transplantation—a comparison between double and triple drug therapy. Clin Transplant. 1994;8:508. [PMC free article] [PubMed]
30. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985;106:522. [PubMed]
31. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cmv-free recipients of livers from seropositive donors. Transplantation. 1996;61:1659. [PMC free article] [PubMed]
32. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc. 1991;23(6):3054. [PMC free article] [PubMed]
33. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation. 1994;57(6):848. [PMC free article] [PubMed]
34. Todo S, Tzakis A, Reyes J, et al. Small intestinal transplantation in humans with or without the colon. Transplantation. 1994;57(6):840. [PMC free article] [PubMed]
35. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK506 rescue in chronic graft versus host disease after bone marrow transplantation. Transplant Proc. 1991;23(6):3225. [PMC free article] [PubMed]
36. Masaoka T, Shibata H, Kakishita E, Kanamaru A, Takemoto Y, Moriyama Y. Phase II study of FK506 for allogeneic bone marrow transplantation. Transplant Proc. 1991;23(6):3228. [PubMed]
37. Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet. 1990;336:402. [PMC free article] [PubMed]